Table 1.

Overall Antibiotic Use and Duration of Therapy over Study Period^*

Antibiotic Use	No. of Orders	Median DOT/1000 Patient-Days (and IQR)
Monthly use, by route
Total antibiotics, any route†	835	2.7 (2.1–3.0)
PO	594	1.9 (1.6–2.4)
IV	208	0.48 (0.41–0.62)
Total use, by class, subclass, or individual drug
Aminoglycosides	10	0.025 (0.006–0.029)
Carbapenems	2	0.059 (0.045–0.072)
Cephalosporins	251	0.043 (0.019–0.049)
First-generation	81	0.043 (0.031–0.062)
Second-generation	54	0.049 (0.019–0.062)
Third-generation	116	0.043 (0.019–0.049)
Clindamycin	15	0.031 (0.019–0.049)
Fluoroquinolones	235	0.043 (0.025–0.049)
Ciprofloxacin	127	0.043 (0.025–0.049)
Levofloxacin	105	0.043 (0.031–0.049)
Moxifloxacin	3	0.049 (0.034–0.151)
Macrolides	56	0.022 (0.006–0.025)
Metronidazole	43	0.049 (0.012–0.062)
Nitrofurantoin	39	0.043 (0.043–0.049)
Penicillins	103	0.043 (0.019–0.049)
Amoxicillin	49	0.043 (0.037–0.049)
Amoxicillin–clavulanate	7	0.062 (0.043–0.241)
Ampicillin	9	0.019 (0.006–0.049)
Cloxacillin	20	0.046 (0.035–0.062)
Penicillin	1	0.006 (0.006–0.006)
Piperacillin–tazobactam	17	0.012 (0.006–0.049)
Rifampin	4	0.043 (0.043–0.043)
Sulfamethoxazole–trimethoprim	41	0.043 (0.019–0.049)
Tetracyclines	16	0.046 (0.043–0.062)
Vancomycin IV	4	0.025 (0.023–0.029)
Vancomycin PO	16	0.028 (0.011–0.062)

DOT = days of therapy, IQR = interquartile range, IV = intravenous, PO = by mouth.

^*Study period was April 1, 2011, to March 31, 2012 (12 months), and the total number of patient-days was 162 080.

^†Routes of administration: IV, oral, gastric tube, intraperitoneal, and topical.